ATE213495T1 - Eine resorbierbare röntgenopake markierung enthaltendes chirurgisches implantat und verfahren zum verriegeln desselben in einem körper - Google Patents
Eine resorbierbare röntgenopake markierung enthaltendes chirurgisches implantat und verfahren zum verriegeln desselben in einem körperInfo
- Publication number
- ATE213495T1 ATE213495T1 AT97941068T AT97941068T ATE213495T1 AT E213495 T1 ATE213495 T1 AT E213495T1 AT 97941068 T AT97941068 T AT 97941068T AT 97941068 T AT97941068 T AT 97941068T AT E213495 T1 ATE213495 T1 AT E213495T1
- Authority
- AT
- Austria
- Prior art keywords
- opacque
- marker
- locking
- same
- surgical implant
- Prior art date
Links
- 239000007943 implant Substances 0.000 title 1
- 239000003550 marker Substances 0.000 title 1
- 102000012289 Corticotropin-Releasing Hormone Human genes 0.000 abstract 2
- 108010022152 Corticotropin-Releasing Hormone Proteins 0.000 abstract 2
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 abstract 2
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000030814 Eating disease Diseases 0.000 abstract 1
- 208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 206010048327 Supranuclear palsy Diseases 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 235000014632 disordered eating Nutrition 0.000 abstract 1
- 208000024714 major depressive disease Diseases 0.000 abstract 1
- 208000028173 post-traumatic stress disease Diseases 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/18—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/06—1,2,4-Triazines
- C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
- C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Materials For Medical Uses (AREA)
- Plural Heterocyclic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2637396P | 1996-09-16 | 1996-09-16 | |
| PCT/US1997/016252 WO1998011075A1 (en) | 1996-09-16 | 1997-09-15 | Pyrazinones and triazinones and their derivatives thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE213495T1 true ATE213495T1 (de) | 2002-03-15 |
Family
ID=21831441
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT97941068T ATE213495T1 (de) | 1996-09-16 | 1997-09-15 | Eine resorbierbare röntgenopake markierung enthaltendes chirurgisches implantat und verfahren zum verriegeln desselben in einem körper |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US6159980A (de) |
| EP (1) | EP0927171B1 (de) |
| JP (1) | JP2001502300A (de) |
| AT (1) | ATE213495T1 (de) |
| AU (1) | AU4270297A (de) |
| CA (1) | CA2265672C (de) |
| DE (1) | DE69710594T2 (de) |
| WO (1) | WO1998011075A1 (de) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR200100574T2 (tr) * | 1998-08-20 | 2001-07-23 | Toyama Chemical Co., Ltd. | Nitrojenöz heteroksiklik karboksamid türevlerini içeren antiviral ajanlar |
| PT1129096E (pt) | 1998-11-12 | 2003-09-30 | Neurocrine Biosciences Inc | Antagonistas de receptor de crf e metodos de tratamento relacionados com os mesmos |
| PT1129091E (pt) | 1998-11-12 | 2003-02-28 | Neurocrine Biosciences Inc | Antagonistas de receptor de crf e metodos relacionados |
| JP2003503476A (ja) * | 1999-07-06 | 2003-01-28 | バーテックス ファーマシューティカルズ インコーポレイテッド | 環化アミド誘導体 |
| US6432989B1 (en) | 1999-08-27 | 2002-08-13 | Pfizer Inc | Use of CRF antagonists to treat circadian rhythm disorders |
| AP2002002620A0 (en) | 2000-02-16 | 2002-09-30 | Neurogen Corp | Substituted arylpyrazines |
| EP1500653A1 (de) * | 2000-02-16 | 2005-01-26 | Neurogen Corporation | Substituierte Arylpyrazine |
| US6515005B2 (en) | 2000-09-21 | 2003-02-04 | Bristol-Myers Squibb Company | Substituted azole derivatives as inhibitors of corticotropin releasing factor |
| US6995157B2 (en) * | 2000-10-27 | 2006-02-07 | Dow Agrosciences Llc | Substituted 4,5-dihydro-1,2,4-triazin-3-ones, 1,2,4-triazin-3-ones, and their use as fungicides and insecticides |
| JP2004519474A (ja) * | 2000-10-27 | 2004-07-02 | ダウ アグロサイエンシィズ エルエルシー | 置換４，５−ジヒドロ−１，２，４−トリアジン−６−オン、１，２，４−トリアジン−６−オン、および殺菌・殺カビ剤ならびに殺虫剤としてのその使用 |
| ES2290313T3 (es) * | 2001-03-15 | 2008-02-16 | Janssen Pharmaceutica N.V. | Derivados de pirazinona que inhiben el vih. |
| CZ20033053A3 (en) | 2001-05-14 | 2004-05-12 | Bristol@Myersásquibbápharmaácompany | Substituted pyrazinones, pyridines and pyrimidines as corticotropin releasing factor ligands |
| AU2002354850B2 (en) | 2001-07-18 | 2008-02-28 | Merck Patent Gmbh | 4-(benzylidene-amino)-3-(methylsulfanyl)-4H-(1, 2, 4) triazin-5-one derivatives having a PDE-IV inhibiting and TNF-antagonistic effect for the treatment of cardiac diseases and allergies |
| US6638981B2 (en) * | 2001-08-17 | 2003-10-28 | Epicept Corporation | Topical compositions and methods for treating pain |
| US6856007B2 (en) * | 2001-08-28 | 2005-02-15 | Tessera, Inc. | High-frequency chip packages |
| US7338969B2 (en) * | 2002-03-08 | 2008-03-04 | Quonova, Llc | Modulation of pathogenicity |
| US7335779B2 (en) * | 2002-03-08 | 2008-02-26 | Quonova, Llc | Modulation of pathogenicity |
| WO2004018437A1 (en) | 2002-08-20 | 2004-03-04 | Neurogen Corporation | 5-substituted-2-arylpyrazines as modulators of crf receptors |
| JP2006506350A (ja) * | 2002-09-12 | 2006-02-23 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | 置換１，４−ピラジン誘導体 |
| US20070196340A1 (en) * | 2003-05-06 | 2007-08-23 | Aldo Ammendola | Modulation of Pathogenicity |
| EP1626965A1 (de) * | 2003-05-09 | 2006-02-22 | Pharmacia & Upjohn Company LLC | Pyrazinone zur verwendung als crf-rezeptor antagonisten zur behandlung von zns-krankheiten |
| GB0420722D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| EP1825729A1 (de) * | 2004-11-30 | 2007-08-29 | Telefonaktiebolaget LM Ericsson (publ) | Leiterplattenbaugruppe mit verbesserter wärmeableitung |
| CN101189214A (zh) * | 2005-05-03 | 2008-05-28 | 美国陶氏益农公司 | 取代的4，5-二氢-1，2，4-三嗪-6-酮、1，2，4-三嗪-6-酮及其作为杀菌剂的用途 |
| JP5193878B2 (ja) * | 2005-12-21 | 2013-05-08 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Ｍｃｈ−１が媒介する疾患における使用のための新規な置換ピラジノン誘導体 |
| AR059898A1 (es) | 2006-03-15 | 2008-05-07 | Janssen Pharmaceutica Nv | Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2 |
| TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
| TW200845978A (en) | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
| US20090011994A1 (en) * | 2007-07-06 | 2009-01-08 | Bristol-Myers Squibb Company | Non-basic melanin concentrating hormone receptor-1 antagonists and methods |
| BRPI0817101A2 (pt) | 2007-09-14 | 2017-05-09 | Addex Pharmaceuticals Sa | 4-(aril-x-fenil)-1h-piridin-2-onas 1,3-dissubstituídas |
| SI2203439T1 (sl) | 2007-09-14 | 2011-05-31 | Ortho Mcneil Janssen Pharm | 1',3'-disubstituirani 4-fenil-3,4,5,6-tetrahidro-2H-1'H-(1,4')bipiridinil-2'-oni |
| CA2716080C (en) | 2008-02-20 | 2016-12-13 | Targia Pharmaceuticals | Cns pharmaceutical compositions and methods of use |
| AU2009221328B2 (en) | 2008-03-05 | 2014-02-27 | Merck Patent Gmbh | Pyrazinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes |
| US7932256B2 (en) * | 2008-07-31 | 2011-04-26 | Bristol-Myers Squibb Company | (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-(6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino)-5-oxo-4,5-dihydropyrazine-2-carbonitrile: a pyrazinone modulator of corticotropin-releasing factor receptor activity |
| ES2439291T3 (es) | 2008-09-02 | 2014-01-22 | Janssen Pharmaceuticals, Inc. | Derivados de 3-azabiciclo[3.1.0]hexilo como moduladores de receptores de glutamato metabotrópicos |
| ES2401691T3 (es) | 2008-11-28 | 2013-04-23 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc. | Derivados de indol y de benzoxacina como moduladores de los receptores metabotrópicos de glutamato |
| MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| SG176018A1 (en) | 2009-05-12 | 2011-12-29 | Janssen Pharmaceuticals Inc | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| ES2440001T3 (es) | 2009-05-12 | 2014-01-27 | Janssen Pharmaceuticals, Inc. | Derivados de 1,2,4-triazolo[4,3-A]piridina y su uso para el tratamiento o prevención de trastornos neurológicos y psiquiátricos |
| CA2814998C (en) | 2010-11-08 | 2019-10-29 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| ES2552455T3 (es) | 2010-11-08 | 2015-11-30 | Janssen Pharmaceuticals, Inc. | Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2 |
| CN103298809B (zh) | 2010-11-08 | 2016-08-31 | 杨森制药公司 | 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途 |
| JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
| JO3367B1 (ar) | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2 |
| IL279202B2 (en) | 2014-01-21 | 2023-09-01 | Janssen Pharmaceutica Nv | Combinations containing positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic subtype 2 receptor and their use |
| US10537573B2 (en) | 2014-01-21 | 2020-01-21 | Janssen Pharmaceutica Nv | Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use |
| RU2718918C2 (ru) | 2014-01-21 | 2020-04-15 | Ньюрокрайн Байосайенсиз, Инк. | Антагонисты рецептора cfr1 для лечения врожденной гиперплазии коры надпочечников |
| BR112021010847A2 (pt) | 2018-12-07 | 2021-09-08 | Neurocrine Biosciences Inc. | Antagonista de receptor de crf1, formulações farmacêuticas e formas sólidas das mesmas para o tratamento de hiperplasia adrenal congênita |
| US12383536B2 (en) | 2019-09-27 | 2025-08-12 | Neurocrine Biosciences, Inc. | CRF receptor antagonists and methods of use |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62198671A (ja) * | 1986-02-25 | 1987-09-02 | Toyo Jozo Co Ltd | １−置換アルキル１，２−ジヒドロ−２−ピラジノン誘導体 |
| DE4134467A1 (de) * | 1991-10-18 | 1993-04-22 | Thomae Gmbh Dr K | Heterobiarylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| AU1191292A (en) * | 1991-02-11 | 1992-09-07 | Schering Agrochemicals Limited | Imidazole pesticides |
| TW229142B (de) * | 1992-04-15 | 1994-09-01 | Nissan Detrochem Corp | |
| FR2692893B1 (fr) * | 1992-06-24 | 1994-09-02 | Sanofi Elf | Dérivés alkylamino ramifiés du thiazole, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent. |
| US6765008B1 (en) * | 1992-12-17 | 2004-07-20 | Pfizer Inc | Pyrrolopyrimidines as CRF antagonists |
| WO1994013661A1 (en) * | 1992-12-17 | 1994-06-23 | Pfizer Inc. | Substituted pyrazoles as crf antagonists |
| TW444018B (en) * | 1992-12-17 | 2001-07-01 | Pfizer | Pyrazolopyrimidines |
| WO1995010506A1 (en) * | 1993-10-12 | 1995-04-20 | The Du Pont Merck Pharmaceutical Company | 1n-alkyl-n-arylpyrimidinamines and derivatives thereof |
| JP3291299B2 (ja) * | 1994-06-06 | 2002-06-10 | ファイザー・インク | コルチコトロピン放出因子（ｃｒｆ）アンタゴニスト活性を有する置換ピラゾール |
| TW574214B (en) * | 1994-06-08 | 2004-02-01 | Pfizer | Corticotropin releasing factor antagonists |
| NZ284846A (en) * | 1994-06-16 | 1998-12-23 | Pfizer | 1-substituted-pyrazolo[3,4-b]pyridin-5-carboxylic acid derivatives, preparation, use, intermediates and pharmaceutical compositions thereof |
| CA2252964A1 (en) * | 1996-04-23 | 1997-10-30 | Merck & Co., Inc. | Pyrazinone thrombin inhibitors |
-
1997
- 1997-09-15 AT AT97941068T patent/ATE213495T1/de not_active IP Right Cessation
- 1997-09-15 JP JP10513924A patent/JP2001502300A/ja active Pending
- 1997-09-15 CA CA002265672A patent/CA2265672C/en not_active Expired - Lifetime
- 1997-09-15 DE DE69710594T patent/DE69710594T2/de not_active Expired - Lifetime
- 1997-09-15 WO PCT/US1997/016252 patent/WO1998011075A1/en not_active Ceased
- 1997-09-15 EP EP97941068A patent/EP0927171B1/de not_active Expired - Lifetime
- 1997-09-15 AU AU42702/97A patent/AU4270297A/en not_active Abandoned
- 1997-09-15 US US08/929,935 patent/US6159980A/en not_active Expired - Lifetime
-
1999
- 1999-08-16 US US09/375,048 patent/US6218391B1/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP0927171A1 (de) | 1999-07-07 |
| CA2265672C (en) | 2008-12-02 |
| WO1998011075A1 (en) | 1998-03-19 |
| CA2265672A1 (en) | 1998-03-19 |
| EP0927171B1 (de) | 2002-02-20 |
| JP2001502300A (ja) | 2001-02-20 |
| AU4270297A (en) | 1998-04-02 |
| DE69710594T2 (de) | 2002-08-29 |
| US6218391B1 (en) | 2001-04-17 |
| DE69710594D1 (de) | 2002-03-28 |
| US6159980A (en) | 2000-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE213495T1 (de) | Eine resorbierbare röntgenopake markierung enthaltendes chirurgisches implantat und verfahren zum verriegeln desselben in einem körper | |
| DE69726724D1 (de) | Tetrahydropteridine und pyridylpiperazine zur behandlung von neurologischen störungen | |
| PL342078A1 (en) | Inhibition of raf kinase using symmetrical and dissymmetrical substituted dimethylureas | |
| PT97446A (pt) | Processo para a preparacao de um derivado de tienobenzodiazepina, util como produto farmaceutico | |
| IL132293A0 (en) | Use of lactoferin in the treatment of allergen induced disorders | |
| PT93110A (pt) | Processo aperfeicoado para a preparacao de derivados de isoquinolina | |
| GR3029561T3 (en) | Pyrrolopyrimidines as crf antagonists. | |
| PL342183A1 (en) | Azolo-triazines and-pyrimidines | |
| WO1997035539A3 (en) | Arylamino fused pyridines and pyrimidines | |
| EG18730A (en) | Substituted tetralin, chromans and related compounds in the treatment of asthma, arthritis and related diseases | |
| PT94993A (pt) | Processo para a preparacao de 17 beta-(ciclopropilamino)-androst-5-en beta-ol 4 substituido e de compostos afins uteis como inibidores de liase c17-c20 | |
| DE69210654D1 (de) | Verwendung von Tomoxetine zur Behandlung von Funktionsstörungen der niedrigen Harnwege | |
| DE3650626D1 (de) | Metallkörper mit behandelter Oberfläche, Verfahren zu dessen Herstellung, diesenverwendendes photoleitfähiges Element und fester Ball für die Oberflächenbehandlung des Metallkörpers | |
| BR9507980A (pt) | Composto composição farmacêutica para uso no tratamento e/ou profilaxia de ansiedade mania depressão desordens associadas com uma hemorragia subaracnóide ou choke neural processo de tratamento e/ou profilaxia de ansiedade mania depressão desordens associadas com uma hemorragia subaracnóide ou choque neural composição farmacêutica uso de um composto | |
| MY107449A (en) | Bcrf1 proteins as inhibitors of interferon- gamma. | |
| ZA902352B (en) | Phytosanitary composition,its process of preparation and its use for treating cryptogamic diseases | |
| EP1645285A3 (de) | Verwendung von Antikörper gegen mag zur Behandlung ischämischer Schlaganfälle | |
| DE69319341D1 (de) | Verfahren und zusammensetzungen zur behandlung von krankheiten verbunden mit mangelhaften immunfunktion | |
| NZ224502A (en) | Silyl alkylene amines and pharmaceutical use, methods for preparation and the treatment of non humans | |
| DE69833727D1 (de) | Verfahren zur Behandlung der Gefässerkrankungen mit aktiviertem Protein C | |
| DE3878529D1 (de) | Vorrichtung zur behandlung von verstauchungen, insbesondere der sprunggelenke sowie zur vermeidung von dabei auftretenden bestimmten komplikationen. | |
| WO1999016406A3 (en) | Therapeutic method | |
| DE69840863D1 (de) | Verfahren zur Herstellung von 2,6-Diaminopurin-2'deoxyribosid und 2'-Deoxyguanosin | |
| EP1380298A3 (de) | Tetrahydropteridines und Pyridylpiperazine zur Behandlung von neurologischen Krankheiten, Anorexia, Entzündungen | |
| DE69433055D1 (de) | Zusammensetzung zum heilen von verletztem gewebe, verfahren für ihre herstellung und ihre verwendung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |